El Injerto Bourbon (Coffea arabica)
El Injerto Bourbon is a heirloom Bourbon-variety Coffea arabica cultivar grown at high altitude in Guatemala's Huehuetenango region, prized for its distinct cup profile. Its primary bioactive compound is caffeine, which exerts effects by competitively antagonizing adenosine A1 and A2A receptors in the central nervous system to promote wakefulness and cognitive performance.

Origin & History
El Injerto Bourbon is a premium Coffea arabica cultivar grown exclusively at Finca El Injerto in Huehuetenango, Guatemala, a family farm established in 1874 that began planting coffee around 1900. The beans are cultivated at 1500-1900m altitude in mineral-rich, non-volcanic soil, hand-picked when ripe, and undergo washed processing with 48-72 hour fermentation before drying.
Historical & Cultural Context
El Injerto Bourbon has no documented role in traditional medicine systems, being a modern specialty coffee cultivar developed for commercial quality and flavor since approximately 1900. While Coffea arabica has historical use in Ethiopian and Arabic traditions for stimulation since the 15th century, this Guatemala-specific variant lacks such traditional context.
Health Benefits
• No clinical evidence exists for health benefits specific to El Injerto Bourbon cultivar • General Coffea arabica meta-analysis shows reduced mortality risk (PMID 28628476) - evidence quality: strong for generic coffee • General arabica coffee contains caffeine for mental alertness (PMID 34589048) - evidence quality: strong for generic coffee • Contains chlorogenic acids with antioxidant properties via Nrf2 pathway - evidence quality: preliminary, no cultivar-specific data • No El Injerto Bourbon-specific health claims can be made based on available research
How It Works
Caffeine, the principal bioactive alkaloid in El Injerto Bourbon arabica, competitively antagonizes adenosine A1 and A2A receptors, reducing inhibitory neurotransmission and increasing dopamine and norepinephrine signaling to enhance alertness and mood. Chlorogenic acids (primarily 5-caffeoylquinic acid) inhibit glucose-6-phosphatase activity and modulate AMPK pathways, contributing to glucose metabolism effects observed in broader arabica coffee research. Diterpenes such as cafestol and kahweol, present in unfiltered preparations, interact with pregnane X receptor (PXR) and affect lipid metabolism and phase II detoxification enzyme expression.
Scientific Research
No human clinical trials, RCTs, or meta-analyses exist specifically for El Injerto Bourbon cultivar. General coffee research includes meta-analyses on mortality risk (PMID 28628476) and RCTs on caffeine effects (PMID 34589048), but these study generic Coffea arabica consumption rather than this farm-specific variant.
Clinical Summary
No randomized controlled trials or observational studies have been conducted specifically on the El Injerto Bourbon cultivar as a health intervention; all clinical evidence is extrapolated from generic Coffea arabica research. A large meta-analysis of prospective cohort studies (PMID 28628476, pooling data from over 200 studies and millions of participants) found that 3–4 cups of coffee daily was associated with the largest risk reduction in all-cause mortality (approximately 17%) and cardiovascular mortality. A meta-analysis of 13 RCTs (PMID 34589048) confirmed that caffeine doses of 40–300 mg improve sustained attention, reaction time, and working memory in healthy adults. Evidence quality for these benefits is strong for generic arabica coffee but cannot be directly attributed to the El Injerto Bourbon cultivar specifically, as no cultivar-level human trials exist.
Nutritional Profile
El Injerto Bourbon is a green/roasted coffee bean cultivar; nutritional data is reported per standard 8oz (240ml) brewed cup unless noted. Macronutrients per brewed cup: calories ~2 kcal, carbohydrates ~0g (trace), protein ~0.3g, fat ~0g, fiber ~0g (grounds contain ~1.1g/100g dry weight). Key bioactive compounds: caffeine ~80-100mg per 8oz brewed cup (Bourbon cultivar beans typically yield 1.1-1.4% caffeine by dry weight, slightly lower than Typica on average); chlorogenic acids (CGA) ~70-140mg per cup predominantly as 5-caffeoylquinic acid (5-CQA), with Bourbon variety known for relatively high CGA retention due to moderate density bean structure; trigonelline ~60-90mg per cup (precursor to niacin, partially converted during roasting to niacin/nicotinic acid ~1-3mg per cup); kahweol and cafestol diterpenes present in unfiltered preparations (~2-4mg combined per cup with paper filter removing ~90%); melanoidins (Maillard reaction polymers) ~25-35% of roasted bean dry weight contributing to antioxidant capacity. Micronutrients per brewed cup: potassium ~116mg (3% DV), magnesium ~7mg (2% DV), niacin (B3) ~0.5mg from trigonelline conversion, riboflavin (B2) ~0.18mg (~14% DV), pantothenic acid ~0.6mg (~12% DV), manganese ~0.05mg. El Injerto estate Bourbon specifically grown at 1,500-1,800m altitude in Huehuetenango, Guatemala; high altitude cultivation correlates with denser beans, elevated sucrose content (~7-9% green bean dry weight vs. ~6% lowland), and elevated malic and citric acid concentrations contributing to characteristic bright acidity. Bioavailability notes: CGAs are 30-70% bioavailable depending on roast level; darker roasts reduce CGA content by up to 70%; caffeine is nearly 100% bioavailable via GI absorption; diterpenes bioavailability is filter-dependent (paper filters trap >90%); potassium and magnesium are well absorbed from coffee matrix.
Preparation & Dosage
No clinically studied dosage ranges exist for El Injerto Bourbon as it lacks biomedical trials. Typical culinary use involves brewing 10-20g of ground beans per cup as standard coffee. No standardized extracts or supplement forms have been studied. Consult a healthcare provider before starting any new supplement.
Synergy & Pairings
No synergistic ingredients studied, general coffee pairs with L-theanine, MCT oil, cocoa, green tea
Safety & Interactions
Caffeine from arabica coffee, including El Injerto Bourbon preparations, can cause insomnia, anxiety, tachycardia, and elevated blood pressure at doses exceeding 400 mg/day in healthy adults, per FDA guidance. Caffeine is a CYP1A2 substrate and inhibitor, meaning it can raise plasma levels of drugs metabolized by CYP1A2 such as clozapine, theophylline, and certain antidepressants; concurrent use warrants caution. Unfiltered preparations (e.g., French press or espresso) retain cafestol and kahweol, which can raise LDL cholesterol by 6–8 mg/dL with habitual consumption, making filtered brewing preferable for individuals managing lipid levels. Pregnant individuals are advised to limit caffeine intake to under 200 mg/day (per ACOG guidelines) due to associations between higher intake and reduced fetal birth weight.